Edition:
India

BioCryst Pharmaceuticals Inc (BCRX.OQ)

BCRX.OQ on NASDAQ Stock Exchange Global Select Market

2.86USD
20 Sep 2019
Change (% chg)

$-0.04 (-1.38%)
Prev Close
$2.90
Open
$2.89
Day's High
$2.92
Day's Low
$2.77
Volume
3,390,398
Avg. Vol
632,786
52-wk High
$9.94
52-wk Low
$2.49

Latest Key Developments (Source: Significant Developments)

Biocryst Pharmaceuticals Says Co, Subsidiary Entered Into Amendment To Second Amended & Restated Credit & Security Agreement, Dated February 5
Monday, 16 Sep 2019 

Sept 16 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST PHARMACEUTICALS INC - CO, SUBSIDIARY ENTERED INTO AMENDMENT TO SECOND AMENDED & RESTATED CREDIT & SECURITY AGREEMENT, DATED FEBRUARY 5.BIOCRYST PHARMACEUTICALS INC - FIRST AMENDMENT TO EXTEND DEADLINE FOR BORROWERS TO DRAW UPON $30 MILLION TRANCHE 2 TO NOVEMBER 30, 2019.BIOCRYST PHARMACEUTICALS - ON SEPT 13, BORROWERS, MIDCAP, AND LENDERS PARTY ENTERED INTO SECOND AMENDMENT TO CREDIT AGREEMENT.BIOCRYST PHARMACEUTICALS INC - SECOND AMENDMENT REVISED DEFINITIONS OF PERMITTED INDEBTEDNESS AND PERMITTED LIENS.BIOCRYST PHARMACEUTICALS - SECOND AMENDMENT TO PERMIT BORROWERS TO INCUR UP TO $1.5 MILLION OF INDEBTEDNESS, FINANCE OF INSURANCE PREMIUMS.  Full Article

Biocryst Reports Q1 2019 Results
Wednesday, 8 May 2019 

May 8 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.28.Q1 REVENUE $5.9 MILLION VERSUS $4.0 MILLION.Q1 REVENUE ESTIMATE $3.1 MILLION -- REFINITIV IBES DATA.Q1 EARNINGS PER SHARE ESTIMATE $-0.27 -- REFINITIV IBES DATA.BIOCRYST CONTINUES TO EXPECT NET OPERATING CASH USE TO BE IN RANGE OF $105 MILLION TO $130 MILLION FOR 2019.CONTINUES TO EXPECT ITS 2019 OPERATING EXPENSES TO BE IN RANGE OF $120 MILLION TO $145 MILLION.  Full Article

Biocryst Pharmaceuticals Reports Q4 Loss Per Share Of $0.25
Monday, 4 Mar 2019 

March 4 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.25.Q4 REVENUE $2.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $2.8 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $-0.25 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $128.4 MILLION AT DECEMBER 31, 2018.  Full Article

Biocryst Advancing Bcx9930 Into Phase 1 Development
Monday, 4 Mar 2019 

March 4 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST ADVANCING BCX9930, AN ORAL FACTOR D INHIBITOR FOR COMPLEMENT-MEDIATED DISEASES, INTO PHASE 1 DEVELOPMENT.BIOCRYST PHARMACEUTICALS INC - BCX9930 SHOWS HIGH POTENCY, SPECIFICITY, SUPPRESSION OF HEMOLYSIS AND WIDE SAFETY MARGIN IN PRECLINICAL STUDIES.BIOCRYST PHARMACEUTICALS INC - PATIENTS CURRENTLY LIMITED TO INTRAVENOUS (IV) INFUSION THERAPY, OR NO THERAPY.BIOCRYST PHARMACEUTICALS INC - PHASE 1 DATA FROM STUDY EXPECTED IN Q4 2019.  Full Article

Biocryst Strengthens Cash Position With Flexible $100 Million Debt Facility
Wednesday, 6 Feb 2019 

Feb 6 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST STRENGTHENS CASH POSITION WITH FLEXIBLE $100 MILLION DEBT FACILITY.BIOCRYST PHARMACEUTICALS INC - NEW LOAN FACILITY INCREASES TO $50 MILLION TO FURTHER EXTEND CASH RUNWAY.BIOCRYST PHARMACEUTICALS INC - ADDITIONAL $30 MILLION AVAILABLE AT COMPANY OPTION FOLLOWING POSITIVE PHASE 3 APEX-2 DATA.BIOCRYST PHARMACEUTICALS INC - ANOTHER $20 MILLION AVAILABLE AT COMPANY OPTION FOLLOWING NDA APPROVAL OF BCX7353 FOR HAE PROPHYLAXIS.BIOCRYST PHARMACEUTICALS INC - NEW LOAN FACILITY REPLACES AN EXISTING $30 MILLION SECURED LOAN FACILITY WITH MIDCAP.BIOCRYST PHARMACEUTICALS INC - BIOCRYST IMMEDIATELY ACCESSES $50 MILLION OF NEW LOAN FACILITY, ADDING $20 MILLION OF NON-DILUTIVE CASH..BIOCRYST PHARMACEUTICALS INC - BIOCRYST INTENDS TO FILE AN NDA FOR BCX7353 BY END OF 2019..BIOCRYST PHARMACEUTICALS INC - TERMS OF NEW LOAN FACILITY PROVIDE THAT BIOCRYST WILL BE IN AN INTEREST-ONLY PAYMENT PERIOD THROUGH JUNE 2020.  Full Article

Biocryst Receives $3.5 Mln For Clinical Trials Of Galidesivir In Yellow Fever
Monday, 17 Sep 2018 

Sept 17 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST RECEIVES ADDITIONAL $3.5 MILLION TO FUND CLINICAL TRIALS OF GALIDESIVIR IN YELLOW FEVER.BIOCRYST PHARMACEUTICALS - NIAID DEVELOPMENT CONTRACT FOR GALIDESIVIR NOW TOTALS $43.0 MILLION.  Full Article

Biocryst reports Q2 loss per share $0.19
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.19.Q2 REVENUE $12.5 MILLION VERSUS $3.1 MILLION.Q2 REVENUE VIEW $3.5 MILLION -- THOMSON REUTERS I/B/E/S.Q2 EARNINGS PER SHARE VIEW $-0.24 -- THOMSON REUTERS I/B/E/S.FY 2018 NET OPERATING CASH USE TO BE IN RANGE OF $85 MILLION TO $105 MILLION.FY 2018 OPERATING EXPENSES TO BE IN RANGE OF $90 MILLION TO $110 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.24, REVENUE VIEW $3.5 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

U.S. FDA Grants Fast Track Designation For Biocryst’S Bcx7353
Monday, 6 Aug 2018 

Aug 6 (Reuters) - BioCryst Pharmaceuticals Inc ::U.S. FDA GRANTS FAST TRACK DESIGNATION FOR BIOCRYST’S BCX7353.BIOCRYST PHARMACEUTICALS - FOCUSED ON COMPLETING PHASE 3 PROGRAM & PREPARING FOR NDA FILING FOR BCX7353 IN H2 2019.  Full Article

BioCryst Pharmaceuticals Commences Public Offering Of Common Stock
Thursday, 2 Aug 2018 

Aug 1 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST PHARMACEUTICALS COMMENCES PUBLIC OFFERING OF COMMON STOCK.  Full Article

Biocryst Pharmaceuticals Entered $30 Million Secured Loan Facility
Saturday, 21 Jul 2018 

July 20 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST PHARMACEUTICALS INC - CO, UNITS, ENTERED A $30 MILLION SECURED LOAN FACILITY - SEC FILING.BIOCRYST PHARMACEUTICALS - USING PROCEEDS OF NEW LOAN TO PAY OFF OUTSTANDING AMOUNTS UNDER PRIOR CREDIT AGREEMENT.  Full Article